Monopar Therapeutics (NASDAQ:MNPR) Shares Gap Up – Here’s Why

Monopar Therapeutics Inc. (NASDAQ:MNPR) gapped up before the market opened on Tuesday . The stock had previously closed at $92.75, but opened at $98.00. Monopar Therapeutics shares last traded at $91.22, with a volume of 8,739 shares.

Analyst Ratings Changes

Several research analysts have commented on the stock. Barclays set a $125.00 target price on shares of Monopar Therapeutics and gave the stock an “overweight” rating in a report on Monday, October 13th. Jones Trading upgraded Monopar Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Friday, October 10th. Raymond James Financial downgraded Monopar Therapeutics from a “strong-buy” rating to an “outperform” rating and lowered their price target for the company from $142.00 to $123.00 in a report on Friday, November 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Monopar Therapeutics in a research report on Wednesday, October 8th. Finally, Lake Street Capital initiated coverage on Monopar Therapeutics in a report on Tuesday, September 23rd. They issued a “buy” rating and a $106.00 target price on the stock. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $106.20.

Monopar Therapeutics Stock Performance

The company has a market cap of $583.56 million, a price-to-earnings ratio of -25.40 and a beta of 1.35. The company’s 50 day moving average price is $83.70 and its 200 day moving average price is $53.94.

Monopar Therapeutics (NASDAQ:MNPR) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.02). On average, equities research analysts forecast that Monopar Therapeutics Inc. will post -1.65 EPS for the current fiscal year.

Insiders Place Their Bets

In other Monopar Therapeutics news, major shareholder Tactic Pharma Llc sold 550,229 shares of the company’s stock in a transaction that occurred on Wednesday, September 24th. The stock was sold at an average price of $63.61, for a total transaction of $35,000,066.69. Following the completion of the sale, the insider owned 272,026 shares of the company’s stock, valued at $17,303,573.86. This represents a 66.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 20.50% of the company’s stock.

Institutional Trading of Monopar Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Goldman Sachs Group Inc. bought a new stake in Monopar Therapeutics during the first quarter valued at about $673,000. AlphaQuest LLC acquired a new position in shares of Monopar Therapeutics during the 1st quarter worth about $44,000. OMERS ADMINISTRATION Corp bought a new stake in Monopar Therapeutics during the 1st quarter valued at approximately $328,000. Affinity Asset Advisors LLC bought a new stake in Monopar Therapeutics during the 1st quarter valued at approximately $2,257,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Monopar Therapeutics in the 2nd quarter valued at approximately $80,000. 1.83% of the stock is currently owned by institutional investors and hedge funds.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.